Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

79.09 -0.45 (-0.57%)
Delayed Quote Updated: 1:44 PM EST, Nov 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BridgeBio Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
News headline image
BridgeBio to Present New Acoramidis Data on Kidney Function, Real-World Outcomes, and First-Line Treatment Patterns in ATTR-CM at the International Symposium on Amyloidosis 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio to Participate in November and December Investor Conferences
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio to Present New Acoramidis Data on Heart Failure Events in ATTR-CM at the American Heart Association Scientific Sessions 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma (NASDAQ:BBIO) Q3 Beat Masks Milestone-Reliant Revenue Ahead of Key PDUFA Catalysts ↗
Via Chartmill
News headline image
Should You Invest $1,000 in BridgeBio Pharma Right Now? ↗
The pharmaceutical company has only two approved therapies, but others should be on the way soon. 
Via The Motley Fool
News headline image
BridgeBio (BBIO) Q3 2026 Earnings Call Transcript ↗
Revenue surged to $353.2 million as Attruby gains traction in rare disease markets. 
Via The Motley Fool
Topics Earnings
News headline image
What BridgeBio Pharma (BBIO) Said on Its Q3 Earnings Call ↗
BridgeBio Pharma (NASDAQ:BBIO) reported third-quarter revenue growth driven by sales of ATTR cardiomyopathy treatment Attruby and a one-time milestone tied to European partner Bayer’s commercialization... 
Via MarketBeat
Topics Earnings
News headline image
BridgeBio Reports Third Quarter 2026 Financial Results and Corporate Updates
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Eyes Four Global Launches by 2027 as Attruby Nears Blockbuster Status ↗
BridgeBio Pharma (NASDAQ:BBIO) expects 2027 to be a transformative year as it expands from one commercial product to four globally launched therapies, President and CFO Thomas Trimarchi said during a... 
Via MarketBeat
News headline image
Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio to Participate in September Investor Conferences
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio (BBIO) Q2 2026 Earnings Call Transcript ↗
Attruby revenue surged to $222.4 million as three pipeline programs entered regulatory review. 
Via The Motley Fool
Topics Earnings
News headline image
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing ↗
Yes, Alnylam has had some bad news. But the bad news isn't as horrible as many think. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.